BACKGROUND: The current recommendation for the treatment of @entity9178 ( @entity9178 ) in solid organ transplant candidates is @entity3109 for 9 months but this treatment has the main problem of frequently reaching the posttransplant period. METHODS: Study of efficacy and safety of a 3 months regimen with @entity3109 and @entity1215 (3HR) in lung transplant candidates in the Reina Sof  a Hospital in C  rdoba. RESULTS: 398 lung transplant @entity1 were evaluated. 92 (24.9%) had @entity9178 and just 22 received the 3HR treatment. One additional @entity1 was treated because he had a history of previous incomplete treatment for active @entity1906 . None of the treated @entity1 developed posttransplant @entity378 compared to 3 of the 62 @entity1 with @entity9178 who were not treated (4.8%). 3 @entity1 could not conclude the 3HR treatment (13%) but only 2 had adverse effects (8.7%). CONCLUSIONS: Treatment of @entity9178 in lung transplant candidates using a short course of 3HR appears to be effective and safe in preventing posttransplant @entity1906 in lung transplant recipients. This article is protected by copyright. All rights reserved.

Efficacy and safety of short-term treatment with @entity3109 and @entity1215 for XXXX in lung transplant candidates.

@entity1 :: ('9606', 'Species') :: ['patients', 'patient'] @entity9178 :: ('MESH:D055985', 'Disease') :: ['LTBI', 'latent tuberculosis infection'] @entity3109 :: ('MESH:D007538', 'Chemical') :: ['isoniazid'] @entity1906 :: ('MESH:D014390', 'Disease') :: ['TB'] @entity1215 :: ('MESH:D012293', 'Chemical') :: ['rifampicin'] @entity378 :: ('MESH:D014376', 'Disease') :: ['tuberculosis']
@entity9178 :: (MESH:D055985,Disease) :: ['latent tuberculosis infection']
